Etid klinik pou Lupus nan Massachusetts
9 etid pou Lupus ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Brigham and Womens Hosp Harvard Med School, Boston
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT05268289Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Boston
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Sep 10, 2026 · NCT06897930A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Boston Medical Center, Boston
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Boston Children's Hospital, Boston
- ak 2 plis
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 26, 2026 · NCT06121297A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- Massachusetts General Hospital, Boston
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 21, 2026 · NCT06570798A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Brigham And Womens Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT07115745Lupus Landmark Study: A Prospective Registry and Biorepository
- Brigham and Women's Hospital, Boston
- University of Massachusetts Memorial Health, Worcester
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Apr 15, 2026 · NCT05934149CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
- CorEvitas, Waltham
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 6, 2026 · NCT06804057Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.